Table 4. BCRP protein expression and... | American Society of Hematology

Table 4.

BCRP protein expression and mitoxantrone accumulation in the individual AML patients

Patient no.	BXP-21/IgG2a ratio		Mitoxantrone, MFI
Patient no.	Primary	Relapse	Primary	Relapse
1	1.57	1.70	761	302
2	4.44	6.56	139	120
3	1.97	6.98	445	115
4	4.83	4.91	111	107
5	2.74	2.15	270	419
6	4.57	7.51	70	44
7	2.85	1.98	165	177
8	1.82	4.05	390	399
9	8.77	9.24	96	89
10	10.06	9.00	155	144
11	3.88	2.94	179	202
12	3.93	4.29	238	322
13	4.42	3.52	488	269
14	8.29	14.49	222	275
15	1.08	1.25	422	292
16	3.33	7.96	354	184
17	nd	nd	202	211
18	2.34	4.63	109	115
19	7.68	2.85	102	126
20	5.88	5.14	127	107

Patient no.	BXP-21/IgG2a ratio		Mitoxantrone, MFI
Patient no.	Primary	Relapse	Primary	Relapse
1	1.57	1.70	761	302
2	4.44	6.56	139	120
3	1.97	6.98	445	115
4	4.83	4.91	111	107
5	2.74	2.15	270	419
6	4.57	7.51	70	44
7	2.85	1.98	165	177
8	1.82	4.05	390	399
9	8.77	9.24	96	89
10	10.06	9.00	155	144
11	3.88	2.94	179	202
12	3.93	4.29	238	322
13	4.42	3.52	488	269
14	8.29	14.49	222	275
15	1.08	1.25	422	292
16	3.33	7.96	354	184
17	nd	nd	202	211
18	2.34	4.63	109	115
19	7.68	2.85	102	126
20	5.88	5.14	127	107

The results are given of BXP-21/IgG2a ratios and mitoxantrone accumulations of the individual patients at diagnosis of the AML and at relapse.